Add to Favorites Newsroom RSS Share
Tampa, FL USA

Our News on Newswise

Men, If You Have HPV, Odds Are You Will Be Reinfected with the Same Type

Men infected with HPV16, the type responsible for most HPV-related cancers, are 20 times more likely to be reinfected with the same type of HPV after one year. That is according to a new study published this month in the Proceedings of the National...
14-Dec-2017 1:05 PM EST Add to Favorites

Moffitt Researchers Discover New Targets for Approved Cancer Drug

TAMPA, Fla. (Oct. 10, 2017) – Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test...
10-Oct-2017 11:00 AM EDT Add to Favorites

New Study Finds Improved Vaccine That Protects against Nine Types of HPV is Highly Effective

TAMPA, Fla. – Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus...
6-Sep-2017 1:05 PM EDT Add to Favorites

Moffitt Cancer Center & Cvergenx Partner to Personalize Radiation Therapy

Moffitt’s Radiation Oncology Department will utilize Cvergenx’s Genomic-Adjusted Radiation Dose (GARD) model.
9-Aug-2017 11:05 AM EDT Add to Favorites

New Research Shows the Power of Radiomics to Improve Precision Medicine

Precision medicine has become the leading innovation of cancer treatment. Patients are routinely treated with drugs that are designed to target specific tumors and molecules. Despite the progress that has been made in targeted cancer therapies, the...
3-Aug-2017 11:05 AM EDT Add to Favorites

Radiation Therapy Prior to Surgery Reduces the Risk of Secondary Tumors in Early-Stage Breast Cancer Patients

Moffitt researchers launched a first of its kind study comparing the long-term benefits of radiation therapy in women with breast cancer either before surgery or after surgery. Their study found that patients who have neoadjuvant radiation therapy...
17-Jul-2017 9:05 AM EDT Add to Favorites

Experimental Drug Co-Developed by Moffitt Cancer Center Researcher Shows Promise

The investigation found that the drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway discovered by Pagano’s group.
14-Jun-2017 1:45 PM EDT Add to Favorites

International Study Identifies New Genetic Risk Factors for Testicular Cancer

Peter Kanetsky, Ph.D., M.P.H., chair of the Cancer Epidemiology Department at Moffitt Cancer Center, and colleagues from the International TEsticular CAncer Consortium (TECAC), launched a large analysis of five major testicular cancer studies to...
13-Jun-2017 9:05 AM EDT Add to Favorites

Our Experts on Newswise

Moffitt Cancer Center HPV Expert Kicked Off EUROGIN Conference

AnnaGiuliano_Euroginopeningtalk_2017.jpg

Anna Giuliano, Ph.D., director of Moffitt Cancer Center’s Center for Infection Research in Cancer, delivered the opening keynote address at the 2017 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International...
10-Oct-2017 10:05 AM EDT

Our YouTube Videos





Chat now!